There is a growing body of evidence that hybrid and decentralized clinical trials are here to stay. What was once a nice-to-have is quickly transforming into a must-have. The catalyst for this dramatic shift was the COVID-19 pandemic. To aid sponsors and CROs in fully realizing the benefits of decentralized clinical trial methods moving forward, this whitepaper extracts the lessons learned from the pandemic and their implications for clinical trials now and in the future.
Enhancing Clinical Trial Flexibility
July 22nd 2024As drug development costs continue to escalate, sponsors are incentivized to find less expensive approaches to develop their assets. FSP models provide increased operational and resourcing flexibility and different pricing plans in comparison to traditional full-service CRO offerings.
Comprehensive and flexible partnership with functional services for rescue study
July 22nd 2024Large CROs operate with a one-size fits all approach, when this no longer worked for a late-stage clinical biopharmaceutical company, they turned to Catalyst Flex to design a tailored solution to meet the safety needs of this rescue study.
The Expanding Role of Functional Service Providers in Clinical Research
July 22nd 2024This article explores the strategic importance of FSPs in clinical research, emphasizing their contribution to cost-efficiency, the acceleration of drug development, and technological innovation in trial management.